Abcam, ab250236, Anti-Prostaglandin E Synthase/MPGES-1 antibody [EPR13765] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Prostaglandin E Synthase/MPGES-1 antibody. Carrier free. Suitable for WB and reacts with Mouse, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13765,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250236 is the carrier-free version of
ab180589
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Prostaglandin E Synthase (MPGES-1) also known as prostin E is a membrane-associated protein that catalyzes the conversion of prostaglandin H2 to prostaglandin E2. It has a molecular mass of about 16 kDa. MPGES-1 is widely expressed in various tissues including the kidneys lungs and heart. The expression of MPGES-1 increases in response to pro-inflammatory signals highlighting its adaptive response during inflammation.
Biological function summary
Prostaglandin E Synthase plays an important role in mediating inflammatory responses and is part of the terminal enzyme complex in the prostaglandin synthesis pathway. Its activity contributes to the elevated production of prostaglandin E2 (PGE2) a bioactive lipid that regulates inflammation fever and pain. MPGES-1 functions in concert with Cyclooxygenase-2 (COX-2) as part of the coordinated induction during inflammatory stimuli.
Pathways
The MPGES-1 enzyme is central to the arachidonic acid cascade specifically in the cyclooxygenase pathway. This pathway leads to the production of prostaglandins which are involved in inflammatory and immune responses. Prostaglandin E2 produced by MPGES-1 is related to proteins such as COX-2 and cytosolic phospholipase A2 (cPLA2) which precede it in the biosynthesis pathway and act collaboratively in the metabolism of arachidonic acid to prostanoids.
MPGES-1 is implicated particularly in conditions like rheumatoid arthritis and cancer. Elevated levels of prostaglandin E2 produced by the concerted action of MPGES-1 have been observed in inflamed joints of arthritis patients correlating with COX-2 expression. In cancer upregulation of MPGES-1 contributes to tumorigenesis through promoting angiogenesis and proliferation. Its interaction with COX-2 enhances oncogenic processes signifying its potential as a therapeutic target.